These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38444612)

  • 41. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
    Kowalczyk M; Rubinstein PG; Aboulafia DM
    J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome].
    Moulis G; Delavigne K; Huguet F; Fortenfant F; Beyne-Rauzy O; Adoue D
    Rev Med Interne; 2011 Dec; 32(12):724-9. PubMed ID: 21864953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management.
    Provan D; Thachil J; Álvarez Román MT
    Expert Rev Hematol; 2024; 17(1-3):55-66. PubMed ID: 38369947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients.
    Palandri F; Catani L; Auteri G; Bartoletti D; Fatica S; Fusco A; Bacchi Reggiani ML; Cavo M; Vianelli N
    Br J Haematol; 2019 Feb; 184(3):424-430. PubMed ID: 30408157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis.
    Weycker D; Hanau A; Hatfield M; Wu H; Sharma A; Bensink ME; Chandler D; Grossman A; Tarantino M
    J Med Econ; 2020 Feb; 23(2):184-192. PubMed ID: 31547724
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort.
    Lucchesi A; Lovrencic B; McDonald V; Newland A; Morgan M; Eriksson D; Wilson K; Giordano G; Carli G; Geldman E; Daykin-Pont O; Prince S; Napolitano M
    Hematology; 2023 Dec; 28(1):2253069. PubMed ID: 37680028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment-a prospective cohort study.
    van Dijk WEM; Poolen GC; Huisman A; Koene HR; Fijnheer R; Thielen N; van Bladel ER; van Galen KPM; Schutgens REG; Urbanus RT
    J Thromb Haemost; 2023 Apr; 21(4):1020-1031. PubMed ID: 36696209
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib.
    Cooper N; Altomare I; Thomas MR; Nicolson PLR; Watson SP; Markovtsov V; Todd LK; Masuda E; Bussel JB
    Ther Adv Hematol; 2021; 12():20406207211010875. PubMed ID: 33995988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: An NIS study.
    Machin N; Ragni MV; Comer DM; Yabes JG
    Thromb Res; 2018 Dec; 172():80-85. PubMed ID: 30384039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
    Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.
    Rovó A; Cantoni N; Samii K; Rüfer A; Koenen G; Ivic S; Cavanna D; Benz R
    PLoS One; 2022; 17(4):e0267342. PubMed ID: 35446925
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
    Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
    Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
    Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
    Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies.
    Kim KJ; Baek IW; Yoon CH; Kim WU; Cho CS
    Br J Haematol; 2013 Jun; 161(5):706-714. PubMed ID: 23530551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines.
    Lozano ML; Revilla N; Gonzalez-Lopez TJ; Novelli S; González-Porras JR; Sánchez-Gonzalez B; Bermejo N; Pérez S; Lucas FJ; Álvarez MT; Arilla MJ; Perera M; do Nascimento J; Campos RM; Casado LF; Vicente V
    Ann Hematol; 2016 Jun; 95(7):1089-98. PubMed ID: 27098812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
    Mingot-Castellano ME; Caparrós IS; Fernández F; Perera-Alvarez MDM; Jimenez-Bárcenas R; Casaus García A; González-Silva M; Yera-Cobo M; Nieto-Hernandez MM; Rodríguez-Fernandez MJ; Díaz-Canales D
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):374-380. PubMed ID: 29738335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune Thrombocytopenia: Characteristics of the Population and Treatment Methods-One-Center Experience.
    Lebowa W; Zdziarska J; Sacha T
    Hamostaseologie; 2023 Apr; 43(2):132-141. PubMed ID: 35654406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.